69
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Strategy of Transfusion in Cardiac Surgery: Limits of Hematocrit and How Much is Too Low?

Pages 141-151 | Published online: 26 Feb 2007

Bibliography

  • Hebert PC , WellsG, BlajchmanMAet al.: A multi-center, randomized, controlled clinical trial of transfusion requirements in critical care. N. Engl. J. Med., 340, 409–417 (1999).
  • Engoren MC , HabibRH, ZachariasA, SchwannTA, RiordanCJ, DurhamSJ: Effect of blood transfusion on long-term survival after cardiac operation.Ann. Thorac. Surg., 74, 1180–1186 (2002).
  • Spiess BD , RoystonD, LevyJHet al.: Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion, 44, 1143–1148 (2004).
  • Goodnough LT , BrecherME, KanterMH, AuBuchonJP: Transfusion medicine. First of two Parts – blood transfusion.N. Engl. J. Med., 340, 438–447 (1999).
  • Madjpour C , SpahnDR: Allogenic red blood cell transfusions: efficacy, risks, alternatives and indications.Br. J. Anaesth., 95, 33–42 (2005).
  • Vamvakas EC , CarvenJH: Allogeneic blood transfusion, hospital charges, and length of hospitalization: a study of 487 consecutive patients undergoing colorectal cancer resection.Arch. Pathol. Lab. Med., 122, 145–151 (1998).
  • A Report by the American Society of Anesthesiologists Task Force on Blood Component Therapy: practice guidelines for blood component therapy. Anesthesiology, 84, 732–747 (1996).
  • Tinmouth A , Chin-YeeI: The clinical consequences of the red cell storage lesion.Transfus. Med. Rev., 15(2), 91–107 (2001).
  • Purdy FR , TweeddaleMG, MerrickPM: Association of mortality with age of blood transfused in septic ICU patients.Can. J. Anaesth., 44(12), 1256–1261 (1997).
  • Zallen G , OffnerPJ, MooreEEet al.: Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am. J. Surg., 178(6), 570–572 (1999).
  • Spahn DR , SchmidER, SeifertB, PaschT: Hemodilution tolerance in patients with coronary artery disease who are receiving chronic beta-adrenergic blocker therapy.Anesth. Analg., 82, 687–694 (1996).
  • Spahn DR , CasuttM: Eliminating blood transfusions: new aspects and perspectives.Anesthesiology, 93, 242–255 (2000).
  • Spahn DR , SeifertB, PaschT, SchmidER: Effects of chronic β-blockade on compensatory mechanisms during acute isovolaemic haemodilution in patients with coronary artery disease.Br. J. Anaesth., 78, 381–385 (1997).
  • Carson JL , NoveckH, BerlinJA, GouldSA: Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion.Transfusion, 42, 812– 818 (2002).
  • Spahn DR , ZollingerA, SchlumpfRBet al.: Hemodilution tolerance in elderly patients without known cardiac disease. Anesth. Analg., 82, 681–686 (1996).
  • Leung JM , WeiskopfRB, FeinerJet al.: Electrocardiographic ST segment changes during acute, severe isovolemic hemodilution in humans. Anesthesiology, 93, 1004–1010 (2000).
  • Zollinger A , HagerP, SingerT, FriedlHP, PaschT, SpahnDR: Extreme hemodilution due to massive blood loss in tumor surgery.Anesthesiology, 87, 985– 987 (1997).
  • DeFoe GR , RossCS, OlmsteadEMet al.: Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann. Thorac. Surg., 71, 769–776 (2001).
  • Dupuis JY , BartB, BrysonG, RobbleeJ: Transfusion practices among patients who did and did not predonate autologous blood before elective cardiac surgery.Can. Med. Assoc. J., 160, 997–1002 (1999).
  • Gandini G , FranchiniM, BertuzzoDet al.: Preoperative autologous blood donation by 1073 elderly patients undergoing elective surgery: a safe and effective practice. Transfusion, 39, 174–178 (1999).
  • Waters JH , LeeJS, KleinE, O‘HaraJ, ZippeC, PotterPS: Preoperative autologous donation versus cell salvage in the avoidance of allogeneic transfusion in patients undergoing radical retropubic prostatectomy.Anesth. Analg., 98, 537–542 (2004).
  • Brecher ME , GoodnoughLT: The rise and fall of preoperative autologous blood donation.Transfusion, 41, 1459–1462 (2001).
  • Alghamdi AA , AlbannaMJ, GuruV, BristerSJ: Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis.J. Card. Surg., 21, 320–326 (2006).
  • Coyle D , LeeKM, FergussonDAet al.: Cost effectiveness of epoetin-α to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics, 18, 161–171 (2000).
  • Marchetti M , BarosiG: Cost-effectiveness of epoetin and autologous blood donation in reducing allogeneic blood transfusions incoronary artery bypass graft surgery.Transfusion, 40, 673–681 (2000).
  • Cross MH : Autotransfusion in cardiac surgery.Perfusion, 16, 391–400 (2001).
  • Daane CR , GolabHD, MeederJH, WijersMJ, BogersAJ: Processing and transfusion of residual cardiopulmonary bypass volume: effects on haemostasis, complement activation, postoperative blood loss and transfusion volume.Perfusion, 18, 115–121 (2003).
  • Svenmarker S , EngstromKB: The inflammatory response to recycled pericardial suction blood and the influence of cell-saving.Scand. Cardiovasc. J., 37, 158–164 (2003).
  • Walpoth BH , EggenspergerN, HauserSPet al.: Effects of unprocessed and processed cardiopulmonary bypass blood retransfused into patients after cardiac surgery. Int. J. Artif. Organs, 22, 210–216 (1999).
  • Schaff HV , HauerJM, GardnerTJet al.: Autotransfusion of shed mediastinal blood after cardiac surgery: a prospective study. J. Thorac. Cardiovasc. Surg., 75, 632–641 (1978).
  • Huet C , SalmiR, FergussonDet al.: A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. Anesth. Analg., 89, 861–869 (1999).
  • De Haan J , SchonbergerJ, HaanJet al.: Tissue-type plasminogen activators and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg., 106, 1017–1023 (1993).
  • Levi M , CromheeckeMEet al., de Jonge E : Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet, 354, 1940–1947 (1999).
  • Sedrakyan A , TreasureT, ElefteriadesJA: Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.J. Thorac. Cardiovasc. Surg., 128, 442–448 (2004).
  • Hill GE , TaylorJA, RobbinsRA: Differing effects of aprotinin and ε-aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression.Ann. Thorac. Surg., 63, 74–77 (1997).
  • Karkouti K , BeattieWS, DattiloKMet al.: A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion, 46, 327–338 (2006).
  • Mangano DT , TudorIC, DietzelC: The risk associated with aprotinin in cardiac surgery.N. Engl. J. Med., 354, 353–365 (2006).
  • Hiatt WR : Observational studies of drug safety – aprotinin and the absence of transparency.N. Engl. J. Med., 355, 2171–2173 (2006).
  • Levy JH : Aprotinin versus tranexamic acid: the controversy continues.Transfusion, 46, 319–320 (2006).
  • McIlroy DR , SilversAJ: Recombinant factor VIIa for life-threatening in high risk cardiac surgery despite full-dose aprotinin.Anesth. Analg., 99, 27–30 (2004).
  • Karkouti K , BeattieWS, WijeysunderaDNet al.: Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score–matched case-control analysis. Transfusion, 45, 26–34 (2005).
  • Bishop CV , RenwickWEP, HoganC, HaeuslerM, TuckfieldA, TatoulisJ: Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.Ann. Thorac. Surg., 81, 875–879 (2006).
  • Martinowitz U , ZaarurM, YaronBL, BlumenfeldA, MartonovitsG: Treating traumatic bleeding in a combat setting: possible role of recombinant activated factor VII.Mil. Med., 169(Suppl. 12), 16–18 (2004).
  • Buehler PW , AlayashAI: Toxicity of hemoglobin solutions; in search of in vitro and in vivo model systems.Transfusion, 44, 1516–1530 (2004).
  • Vane LA , FunstonJS, KirschnerRet al.: Comparison of transfusion with DCLHb or pRBCs for treatment of intraoperative anemia in sheep. J. Appl. Physiol., 92, 343–353 (2002).
  • Stowell CP : What happened to blood substitutes?Transfus. Clin. Biol., 12(5), 374–379 (2005).
  • Simon TL , AlversonDC, AuBuchonJet al.: Practice parameter for the use of red blood cell transfusions: developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American pathologists. Arch. Pathol. Lab. Med., 122, 130–138 (1998).
  • Spahn DR , SchanzU, PaschT: Perioperative transfusionskriterien.Anaesthesist, 47, 1011–1020 (1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.